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Background: The cost of exacerbations in chronic obstructive pulmonary disease (COPD)
has not been well studied. The aim of this study was to identify and quantify the (average)
cost of moderate and severe exacerbations (ME and SE, respectively) from a Canadian
perspective.
Methods: Resources used during ME and SE were identified in a year long prospective,
observational study (Resource Utilization Study In COPD (RUSIC)). The units of analysis
were ME and SE. Unit costs (2006$CAN), based on provincial, hospital and published
sources, were applied to resources. The overall cost per ME and SE were calculated. The
population burden of exacerbations was also calculated.
Results: Among study participants (N ¼ 609, aged 68.679.4 years, 58.3% male) there
were 790 exacerbations: 639 (80.9%) MEs and 151 (19.1%) SEs. Of the 790 exacerbations,
618 (78.2%), 245 (31.0%) and 151 (19.1%) included a visit to an outpatient clinic,
emergency department (ED) or hospital, respectively. For ME, 85.9% and 13.1% involved
visits to GPs and respirologists, respectively. Pharmacologic treatment changes in the
outpatient setting involved antibiotics (63.1%) and corticosteroids (34.7%). The overall
mean costs for outpatient and ED services for MEs were $126 (N ¼ 574) and $515 (N ¼ 105),
respectively. The average overall cost of a ME was $641. For SEs, the average hospital stay
was 10.0 days. The overall mean costs of outpatient, ED and hospitalization services for SEElsevier Ltd. All rights reserved.
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N. Mittmann et al.414were $114 (N ¼ 44), $774 (N ¼ 140) and $8669 (N ¼ 151), respectively. The average
overall cost of a SE was $9557.
Conclusion: The economic burden associated with MEs and especially SEs, in Canada, is
considerable and likely has a substantial impact on healthcare costs. The overall burden of
exacerbations has been estimated in the range of $646 million to $736 million per annum.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is character-
ized by progressive airway obstruction which is not
completely reversible with bronchodilator medications.1
Exacerbation symptoms include increased dyspnea, cough,
and sputum, as well as changes in sputum colour. Exacer-
bations are associated with a significant worsening of
pulmonary function2 and are considered the key drivers, in
terms of increased medical visits and hospitalizations, in the
costs of COPD.3
COPD is a serious public health problem in many countries
throughout the world.4 According to World Health Organiza-
tion (WHO) estimates, 80 million people have moderate to
severe COPD and three million people died of COPD in 2005.
WHO predicts that COPD will become the fourth leading
cause of death worldwide by 2030.5 Important risk factors
include tobacco smoking, indoor air pollution (such as
biomass fuel used for cooking and heating), outdoor air
pollution and occupational dusts and chemicals (vapours,
irritants, and fumes).5 The burden of COPD extends beyond
the patient and to the health care system and society as a
whole.
A number of studies have attempted to estimate the
burden of COPD using various research techniques (e.g.,
retrospective telephone surveys, database analyses).6–14
The majority of studies have assessed the overall burden
of COPD in general. However, two studies have specifically
evaluated the cost associated with exacerbations. Anders-
son et al.13 examined the cost of COPD exacerbations by
severity by surveying 202 individuals previously identified in
an ongoing longitudinal survey in Sweden. Results showed
that exacerbations accounted for 35–45% of the total health
care cost of COPD. Moderate and severe exacerbation costs
were SEK 2111 and SEK 21852, respectively. In the other
study, Miravitlles et al.14 identified 2414 Spanish COPD
patients treated for an acute exacerbation in a primary care
setting. The study prospectively collected 30 days of
resource use data in order to assess the total costs
associated with the management of acute exacerbations
and relapses. A mean cost of $159 US per exacerbation was
reported, where an exacerbation was based on clinical
criteria. Costs were not stratified by exacerbation severity.
Canada has a publicly funded health care system that
provides universal, comprehensive coverage for medically
necessary hospital and physician services. These services are
administered and delivered by provincial and territorial
governments.15 In Canada, 750,000 people have been
diagnosed with COPD by a health professional.16 COPD is
the fourth leading cause of death in Canada, after heart
disease, cancer, and stroke.17 Prevalence rates for men and
women over the age of 35 years are 2.8% and 3.6%,respectively.16 The true prevalence is thought to be under-
estimated.6 The recent publication of the Burden of
Obstructive Lung Disease (BOLD) appears to confirm that
previous prevalence estimates are low.18
A recently published Canadian 52 week, prospective,
multicentre, observational study, Resource Utilization Study
In COPD (RUSIC), reported the health care resources
associated with moderate and severe exacerbations in COPD
patients who completed the year long study.19 609 patients
were recruited by 50 sites located in all 10 provinces in
Canada. Sites ranged from urban and rural primary care
settings. Physicians included community and academic
respirologists (the ratio of community to academic physi-
cians was representative of the Canadian physician popula-
tion). Study physicians were instructed to enrol the next
eight to 10 eligible patients during regular office/clinic
visits. Inclusion criteria were willingness to provide in-
formed consent, a diagnosis of stable COPD (airway
obstruction with FEV1 of 65% or less and a FEV1/FVC of
71% or less) with a pulmonary function test within 6 months
of visit 1 (a test within 10 days of visit 1 was deemed
acceptable),440 years old, current or ex-smokers with a 10
pack-year history. Patients were excluded if they had a
history of other lung disease (asthma, cystic fibrosis,
bronchiectasis, interstitial lung disease, pulmonary throm-
boembolic disease), other medical conditions deemed to
prevent compliance and completion of study, receiving an
investigational drug 30 days prior to screening visit, were
participants in another clinical trial, living outside of Canada
for 48 consecutive weeks.
An exacerbation was defined as a complex of COPD-
related symptoms including one or more of the following:
cough, wheeze, dyspnea, or sputum production lasting X3
days. Exacerbations were categorized as mild, moderate or
severe based on definitions used in prospective clinical
trials. Only health resource utilization (HRU) associated with
moderate and severe exacerbations was collected. The
definitions for exacerbation severity were: Moderate exacerbation—visit to an outpatient facility,
including an emergency department (ED) (but not
requiring admission to hospital) and an alteration in
medication (for example, addition of antibiotics or oral
corticosteroids). Severe exacerbation—hospitalization.
All resource information was collected prospectively. Data
for HRU attributable to moderate and severe exacerbations
were collected in a standardized fashion. Records of
patients who experienced an exacerbation were reviewed
and medications and outcomes were documented. All
concomitant medications were recorded, including rescue
ARTICLE IN PRESS
The cost of COPD exacerbations to the Canadian healthcare system 415use of short-acting inhaled beta-agonists. Information on
non-scheduled contacts with physicians and other health
care providers that were due to an exacerbation of COPD,
including date, reason for contact, medications prescribed,
outcome (e.g., discharge, admission to hospital, follow-up
visit), disability days and employment status was collected
prospectively using a standardized questionnaire. To aid
with the accuracy of information recorded in diaries,
patients were contacted by study coordinators every 5–6
weeks in order to obtain information on exacerbations over
the previous time horizon. Resource utilization information
collected included number of exacerbation-related hospita-
lizations, hospital length of stay, number of unscheduled
physician visits, number of ED visits, home care and
community services, allied health professional visits, med-
ications, diagnostics and laboratory values.
Among study participants (N ¼ 609), the mean age of the
patient population was 68.6 years (SD 9.4) and the majority
of patients were male (58.3%). Mean FEV1 was 1.01L (SD
0.4L), 43.9% predicted (SD 14.3%), with an average smoking
history of 47.9 pack years (SD 23.5). Most patients were
taking a bronchodilator (99.6%). Ninety-seven patients were
admitted to hospital with an average length of stay of 10.0
days.
Patient characteristics are summarized elsewhere in
detail and may be considered representative of the
Canadian COPD population.19,20
The objectives of this study were to quantify the
resources collected in the RUSIC study and to calculate
the average cost of a moderate and a severe exacerbation.
The other objective was to use those exacerbation costs to
estimate the national burden of moderate and severe COPD
exacerbations in Canada.
Methods
Study design
The perspective of the analysis was that of the Canadian
provincial health care system. The units of analysis/costing
were a moderate and a severe exacerbation, (ME and SE,
respectively). HRU data associated with ME and SE, namely
ED visits, outpatient visits and hospitalizations, were
collected. Outpatient resources included physician visits,
laboratory and diagnostic testing, mode of transportation to
visit and change in medication. ED resources included ED
visit (physician cost+visit cost), mode of transportation and
change in medication. Hospital resources consisted of
physician visits, length of stay, type of bed (ward/ICU),
mode of transportation, change in medication and labora-
tory/diagnostic testing. Concomitant medications including
rescue drugs were considered. Information on scheduled and
non-scheduled contacts with physicians and other health
care providers due to an exacerbation included date,
reason, medications prescribed, outcome (e.g., discharge,
admission), transportation and tests.
Cost determination
2006 Canadian unit costs were applied to the resource
utilization elements of ME and SE. Unit costs were applied toresources utilized by the patient population (Table 1). Costs
were obtained from provincial sources, hospital databases
and published sources (Ontario Case Costing Initiative,
Ontario Schedule of Benefits, Ontario Drug Benefit Formu-
lary, published literature). All variables were reviewed by
the clinical experts for appropriateness. Costs obtained in
non-2006 dollars were inflated using the Canadian Consumer
Price Index. Discounting was not applied to costs or
outcomes given the 1 year time horizon. Costs were
presented in a format similar to an intent to treat analysis
(ITT) and a clinically evaluable (CE) analysis. For the
ITT analysis, the denominator for the total number of ME
and SE was used to determine the average cost per
exacerbation. For the CE analysis, the denominator was
based on the number of exacerbations that used a resource
variable. The difference between the two analyses is
illustrated below: ITT analysis: Forty-four exacerbations used outpatient
resources but 19 of those exacerbations used laboratory/
diagnostic test resources. The mean cost per laboratory/
diagnostic tests was based on the total number of
exacerbations (N ¼ 44). CE analysis: Forty-four exacerbations used outpatient
resources but 19 of those exacerbations used laboratory/
diagnostic test resources. The mean cost per laboratory/
diagnostic tests was based on the total number of
exacerbations with laboratory/diagnostic tests (N ¼ 19).
Assumptions
Several assumptions were made. Exacerbation episodes 47
days apart were considered to be separate events. All
resource use that preceded a hospitalization was included in
the SE category if it occurred within 7 days of hospitalization
(e.g., patient visited an ED on day 1 but was hospitalized
on day 2, the resources associated with the ED were
considered severe exacerbation costs). Double counting
was avoided with a hierarchy of rules. Costs were applied
to the first point of contact for the patient during
the exacerbation (e.g., ED, outpatient or inpatient).
Medication utilization was applied to each area (ED,
outpatient and inpatient). Medication costs were based on
a 1 month drug treatment duration post ME/SE. For
medications, salbutamol and salmeterol were used to
represent all short-acting beta-agonists (SABAs) and long-
acting beta-agonists (LABAs), respectively.21 Costs asso-
ciated with pulmonary function testing were assumed to
be simple spirometry rather detailed pulmonary function
(unlikely to be conducted at time of exacerbation).
Ciprofloxacin represented antibiotic utilization and predni-
sone represented corticosteroid use. Resources not utilized
were costed at $0.
Analyses
The primary analysis calculated the overall mean cost of a
ME and a SE based on the ITT analysis. Mean value is used in
preference to median, as mean value is a parametric
estimate of interval data. A secondary analysis calculated
the overall mean cost per exacerbation based on the CE
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Table 1 Unit cost list.
Description Cost (2006 $ CAD) Source
Drugs (per month)
Inhaled corticosteroid $64.02 Ontario Drug Benefit Formulary (ODBF)
Oral corticosteroid $1.00 ODBF
Theophylline $15.16 ODBF
Anticholinergic (short acting) inhaled $68.12 ODBF
Beta agonist (long acting) inhaled $60.53 ODBF
Beta agonist (short acting) inhaled $6.26 ODBF
Leukotriene receptor antagonist $55.92 ODBF
Antibiotic $28.60 ODBF
Physician
General practitioner $58.20 Ontario Schedule of Benefits (OSB) version July 1, 2006
Respiratory specialist $58.25y OSB
Other specialist $58.25 OSB
Emergency physician $86.10 OSB
Allied health professionals
COPD case manager (RN) $35.80 Ontario Nurses’s Ass (ONA) http://www.ona.org/faq/
index.html#ont_sal
Laboratory/diagnostics
Spirometry $17.05 Ontario Schedule of Laboratory Fees (OSLF)
Blood gases $47.05 OSLF
Sputum $11.37 OSLF
Urine $2.59 OSLF
X-ray chest $32.05 OSLF
Bronchial endoscopy $184.61 OSLF
ECG $105.95 OSLF
Outpatient/Inpatient tests
Arterial blood gases $17.89 OSB/OSLF
Auscultation $30.70 OSB/OSLF
CAP gases NA OSB/OSLF
Oximetry $4.30 OSB/OSLF
Peak flow $28.80 OSB/OSLF
Pulmonary function test $154.38 OSB/OSLF
Transportation
Ambulance $845.61 http://www.health.gov.on.ca/english/public/program/
ehs/land/service_qa.html
House call $41.75 OSB
Nurse home care $20.60 http://www.eldercarehomehealth.com/Rates.html
Rehabilitation
Inpatient+outpatient $17,122 29
Outpatient programme (6 weeks) $1600 30
Oxygen
Oxygenz $0.00 http://www.health.gov.on.ca/english/public/pub/adp/
pdf/oxygen.pdf
Full reimbursement by OMOH ADP oxygen program
Due to exacerbation billed as general assessment.
yDue to exacerbation billed as medical specific assessment.
zNo oxygen volume information was collected in the RUSIC study, therefore not possible to cost.
N. Mittmann et al.416analysis. Descriptive statistics for both resource utilization
and costs were calculated. Continuous clinical and cost data
were reported as means7standard deviations (SD). Data
were analysed using SAS Version 9.1.The national cost of exacerbations was estimated in two
ways: (1) based on the national COPD population hospita-
lization statistics and (2) based on the exacerbation rate
observed in RUSIC.
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Table 3 Cost of moderate exacerbations.
Intent to treat
analysis average
cost (Mean7SD)
Clinically evaluable
analysis average
cost (mean7SD)
Outpatient resources (N ¼ 574)
Outpatient
physician
visits
$617$14 $617$13
(N ¼ 574) (N ¼ 570)
Median: $58 Median: $58
Range: $0–$180 Range: $58–$180
Laboratory
and diagnostic
tests
$167$37 $497$50
(N ¼ 574) (N ¼ 185)
Median: $0 Median: $32
Range: $0–$370 Range: $3–$370
Transportation $237$70 $257$72
(N ¼ 574) (N ¼ 535)
Median: $23 Median: $20
Range: $0–$866 Range: $0–$866
Medication
changes
$26724 $307$23
(N ¼ 574) (N ¼ 494)
Median: $29 Median: $29
Range: $0–$182 Range: $0–$182
Total
outpatient
resource cost
$126 $165
Emergency resources (N ¼ 105)
Emergency
department
visit
$2527$0 $2527$0
(N ¼ 105) (N ¼ 105)
Median: $252 Median: $252
Range: $252–$252 Range: $252–$252
Transportation $2417386 $3137$413
(N ¼ 105) (N ¼ 81)
Median: $20 Range: $0–$1500
Range: $0–$1500 Median: $20
Medication
changes
$21724 $267$24
(N ¼ 105) (N ¼ 84)
Median: $29 Median: $29
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There were 790 episodes of exacerbations during the study
period, of which 639 (80.9%) were classified as moderate
and 151 (19.1%) were severe. Of the 790 exacerbations, 618
(78.2%) used outpatient resources, 245 (31.0%) used ED
resources, and 151 (19.1%) were hospitalized (Table 2).
Moderate exacerbations
Outpatient visit resources
85.9% of ME involved a visit to a general practitioner, 13.1%
to a respirologist, 3.3% to an emergency physician, and 1% to
other. The most common outpatient laboratory and diag-
nostic tests conducted were chest X-rays (19.5%), followed
by spirometry (9.8%). The mode of transportation to the
outpatient visits was primarily private car (77.0%), with only
0.7% of ME involving an ambulance. Medication changes
occurred with antibiotics (63.1%), corticosteroids (34.7%)
and beta-agonists (12.4%).
Emergency department resources
In the ED, 47.6% and 47.6% of ME episodes had changes to
corticosteroids and antibiotics, respectively. Transportation
to the ED involved the use of a private car in 43.8% of ME, an
ambulance in 25.7%, and the remaining cases arrived by
public transportation or did not report transportation.
Costs
The average overall cost of a ME was $641 ($126 out-
patient+$515 ED). The cost drivers for MEs were ED visit and
mode of transportation to the ED. When exacerbations were
weighted by resources used, the average overall cost was
$756 ($165 outpatient+$591 ED) (Table 3).
Severe exacerbations
Hospitalization resources
Resources were stratified into inpatient hospital, ED and
outpatient costs. The majority of patients (80.8%) were
discharged from hospital to their home.Table 2 Number of exacerbation events by severity and
location.
Resource
utilization
variable
All
exacerba-
tions
(N ¼ 790)
Moderate
exacerba-
tion
(N ¼ 639)
Severe
exacer-
bation
(N ¼ 151)
Outpatient
visits
618 574 44
Emergency
department
visits
245 105 140
Hospitaliza-
tion
151 N/A 151
By definition, a severe exacerbation must include a
hospitalization.
Range: $0–$104 Range: $0–$104
Total
emergency
resource cost
$515 $591
Total ME cost $641 $756Hospital resources
The average length of hospital stay due to an exacerbation
was 10.0 days (714.5 days). Sixteen percent of patients
were in an ICU for an average of 6.2 days (76.5 days). 57.6%
and 44.4% of exacerbations involved changes in antibiotic
and corticosteroid medications while in hospital, respec-
tively. The most common inpatient laboratory and diagnos-
tic tests were blood tests (94.0%), chest X-rays (88.1%) and
ECG (65.6%). 13.2% of SE episodes arrived to hospital via
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Table 4 Cost of severe exacerbations.
Intent to treat
analysis average
cost (mean7SD)
Clinically evaluable
analysis average cost
(mean7SD)
Hospital resources (N ¼ 151)
Hospital stay $70607$10,826 $70607$10,826
(N ¼ 150) (N ¼ 150)
Median: $4263 Median: $4263
Range:
$609–$100,426
Range: $609–$100,426
Laboratory
and diagnostic
tests
$14837$1036 $14837$1036
(N ¼ 151) (N ¼ 151)
Median: $1959 Median: $1959
Range: $17–$4072 Range: $17–$4072
Transportation $1257$312 $4117$453
(N ¼ 151) (N ¼ 46)
Median: $0 Median: $20
Range: $0–$1646 Range: $0–$1646
Total hospital
resource cost
$8669 $8954
Emergency resources (N ¼ 140)
Emergency
department
visit
$25270 $25270
(N ¼ 140) (N ¼ 140)
Median: $252 Median: $252
Range: $252–$252 Range: $252–$252
Transportation $4967418 $4997$417
(N ¼ 140) (N ¼ 139)
Median: $846 Median: $846
Range: $0–$1500 Range: $6–$1500
Medication
changes
$257$30 $337$31
(N ¼ 140) (N ¼ 105)
Median: $29 Median: $30
Range: $0–$104 Range: $0–$104
Total
emergency
resource cost
$774 $786
Outpatient resources (N ¼ 44)
Outpatient
physician
visits
$727$46 $837$39
(N ¼ 44) (N ¼ 38)
Median: $58 Median: $58
Range: $0–$203 Range: $36–$203
Laboratory
and diagnostic
tests
$247$51 $827$65
(N ¼ 44) (N ¼ 13)
Median: $0 Median: $50
Range: $0–$206 Range: $11–$206
Transportation $57$9 $197$4
(N ¼ 44) (N ¼ 12)
Median: $0 Median: $20
Range: $0–$20 Range: $6–$20
Medication
changes
$137$24 $297$30
(N ¼ 44) (N ¼ 19)
Median: $0 Median: $29
Range: $0–$104 Range: $0–104
Table 4 (continued )
Intent to treat
analysis average
cost (mean7SD)
Clinically evaluable
analysis average cost
(mean7SD)
Total
outpatient
resource cost
$140 $213
Total SE cost $9557 $9953
Although 151 exacerbations resulted in hospitalizations,
one case did not have a discharge date. Consequently, the
mean hospital stay cost was based on 150 exacerbations.
N. Mittmann et al.418ambulance, private car (8.6%) and other transportation
modes (13.2%) (which could include transfers from other
institutions). There was no transportation information
available for 45.0% of the SE episodes.
Outpatient resources
For outpatient physician visits, 38.6% of SE involved a visit to
a general practitioner, 34.1% to an ED physician, 22.7% to a
respirologist and 11.4% to another physician. The most
common outpatient laboratory and diagnostic tests con-
ducted were chest X-rays (20.5%), blood tests (13.6%),
sputum analysis (9.1%) and spirometry (6.8%).
Emergency resources
92.7% of SE involved use of the ED prior to hospitalization.
Transportation to the ED involved an ambulance in 56.4% of
the SE episodes.
Costs
The average overall cost of a SE was $9557 ($774 ED+$114
outpatient+$8669 hospitalization). The cost drivers for SE’s
were hospital length of stay and inpatient laboratory and
diagnostic testing. When exacerbations were weighted by
resources used, the average overall cost for a SE was $9953
($786 ED+$213 outpatient+$8954 hospitalization) (Table 4).
Deaths
Thirty-three (5.4%) deaths were reported in RUSIC. Eighteen
deaths were reported among patients who were hospita-
lized. The cause of death was not always reported. Four
patients with SE episodes died during hospitalization. Non-
COPD-related deaths such as lung cancer, complications
from COPD and a scooter accident were recorded, however,
the majority of cases did not have a reason for death
reported.
National burden of moderate and severe
exacerbations
We used two different methods to estimate the National
exacerbation rate per year. Both methods applied different
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one for the COPD) in order to determine the national cost.
The first method used published estimates of COPD-
related hospitalizations obtained from Canadian hospitaliza-
tion data. There were approximately 60,000 hospital
admissions due to COPD in Canada in 1997.22 If we assume
that all of these COPD-related hospitalizations are as a
result of SEs (per the definition used in this study) we are
able to calculate an estimate of the annual burden of SEs in
Canada. Based on our estimates of the cost of a SE (i.e.,
$9557), the annual national burden of severe exacerbations
alone is approximately $573 million. Current estimates
predict that COPD-related hospitalizations will double by
the year 2015, thereby increasing the national cost of SE to
over $1 billion per annum. To estimate the number of MEs in
Canada, we used the ratio of moderate to severe exacer-
bations as observed in the RUSIC study (639 moderate:151
severe). Applying this ratio to the 60,000 estimated SEs
results in approximately 250,000 MEs nationally. At $641 per
ME, this would translate into a national annual cost of $163
million. When combined, the burden of ME and SE in Canada
exceeds $736 billion dollars per annum.
The second method calculated the national burden of
illness using RUSIC specific data. In RUSIC, during the year of
observation, 278 (53.1%) of the COPD patients had an
exacerbation. There were 691 exacerbations (2.5 exacerba-
tions per patient), of which 615 (89.0%) were ME. Based on
published estimates, there are approximately 750,000
patients diagnosed with COPD in Canada.16 If 53.1% of COPD
patients have exacerbations (N ¼ 398,250), then 354,443
have MEs and 43,807 have SEs in Canada. At $641 per ME and
$9557 per SE, the national cost burden would be $227
million and $419 million, respectively. When combined, the
burden of moderate and severe exacerbations in Canada
exceeds $646 million dollars per annum. These values do not
take into account the cost associated with mild COPD
(where patients may experience ME or SE) and the economic
burden of mild exacerbations.Discussion
Determination of the cost of an exacerbation is important
for two main reasons, namely resource allocation and
economics. From a resource allocation perspective, costing
by exacerbation provides insight into direct medical
expenditures borne by the health care system and aids in
the resource allocation planning. From an economic
perspective, this information helps to put into context the
value of treatments or programs that prevent or reduce the
number of exacerbations, or reduce the severity of exacer-
bations.
This study is unique in that it is the first study to
prospectively examine the economic burden of moderate
and severe COPD exacerbations from a Canadian perspective
based on the resources collected in a 1 year long prospective
study that examined a large cohort of COPD patients.
Our results show that the overall cost per moderate
exacerbation was $641 and $9557 for a severe exacerbation.
The ITT average cost of exacerbation is not substantially
different from the CE estimate. The key cost driver in severe
exacerbations was hospitalization, with an average length ofstay of 10 days, accounting for 73% of the total cost.
Laboratory, diagnostic and medication costs were generally
overshadowed by hospitalization, clinic and ED visits.
Transportation costs were also considerable.
Based on this average cost, our calculation showed a
national cost burden for moderate and severe exacerbations
of $646–736 million (CAN). This value may be an under-
estimate given that the prevalence of moderate exacerba-
tions is not well documented, COPD is under-diagnosed and
prevalence of hospitalization due to COPD is increasing.6
Because of the health care system perspective used, these
estimates only include direct costs and do not take into
account societal costs such as caregivers or lost wages.
Our study builds on the results of other economic analyses
investigating the burden of COPD and COPD exacerba-
tions.6–14 Miravitlles et al.14 reported an average cost of
exacerbation at $159. Costs were based on a cohort of 2414
patients over a 1 month time horizon. This value was
calculated as the weighted average cost per exacerbation
where only a small proportion (3.4%) of the population
investigated were hospitalized at a cost of $2652. The mean
cost was primarily based on medication costs, outpatient
clinic visits and ED costs. Study patients were recruited
through primary practices and thus represented a milder
COPD population. Long-term time horizons and the cost of
patients presenting directly to hospitals with severe
exacerbations were not evaluated as in the present study.
Andersson and colleagues reported costs of moderate and
severe exacerbation at SEK 2111 and SEK 21852, respec-
tively. The small study cohort (N ¼ 61) was based on a larger
epidemiological cohort. Definitions of mild, mild/moderate,
moderate and severe exacerbations were different than
those used in the present study. The cost driver in the severe
category was hospitalization cost, which accounted for more
than 90% of the overall mean cost. However, the average
length of stay (6.6 days) was approximately half of that
found in the RUSIC study.19 Patients were required to recall
events occurring over a previous 4–6 months time horizon
which may introduce recall bias.13
The Confronting COPD in North America and Europe study
was a large international retrospective survey that exam-
ined the burden of COPD in eight different countries.6–12
That study used telephone interviews with physicians and
patients to collect information on symptom severity and
frequency, management and treatment, quality of life,
health care resource utilization and lost productivity. This
retrospective survey relied on the 12-month recall of
patients for COPD-related hospitalizations, ED visits, pri-
mary care consultations, treatment and laboratory tests.23
Costs were derived by multiplying the unit cost of a resource
by the frequency of the resource use in currency of the
country studied. Recall bias was a major limitation of the
international study. Chapman and colleagues examined
the burden of illness of COPD, not exacerbation-related
costs, from a Canadian perspective using telephone surveys
to document direct and indirect costs. Here, the direct cost
was $2000 per COPD patient annually.6 This is a weighted
cost for all severities. Limitations of that study included the
telephone sampling method, patient recall bias and the
study did not use exacerbation-specific severity informa-
tion. The overall national burden was not reported in that
study. However, if we extrapolate the $2000 per COPD
ARTICLE IN PRESS
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(750,000), the national burden of illness for Canada would
be $1.5 billion. This estimate is inline with our national
calculations.
The results presented in this study are considered to be a
conservative estimate of the real cost of an exacerbation.
Only resource utilization data collected during the prospec-
tive study was available for costing. Indirect costs asso-
ciated with moderate and severe exacerbations were not
considered as part of this perspective but would increase
the overall cost of an exacerbation. The study did not
collect information on the volume of oxygen used per
patient. Although most patients likely received oxygen
therapy, the cost of this therapy is not likely to be
significant.24 In this study, medication use was based on
the cost of a 1 month period, however longer utilization
would lead to increased costs. Long-term medication use
may occur as the recovery period after a COPD exacerbation
is quite prolonged.2,25 This is unlike asthma, where a patient
may have a severe life threatening asthma exacerbation and
return to normal lung function relatively quickly.
The economic burden associated with moderate exacer-
bations and especially severe exacerbations is considerable
from a health care system and national perspective. Based
on the anticipated increase in health care utilization by
patients with COPD, a multifaceted approach to improve
COPD management would likely be successful in substan-
tially reducing health care costs. Interventions should
include optimization of the maintenance treatment of
patients with COPD,26 better use of chronic disease manage-
ment strategies,27 greater access to pulmonary rehabilita-
tion16 and systemic corticosteroid utilization to treat acute
exacerbations.28Conclusions
The economic burden associated with moderate and
especially severe COPD exacerbations is considerable for
the Canadian health care system and national perspective.
Focus on the prevention of exacerbations through medical
and non-medical interventions may reduce these overall
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